Affiliation:
1. ERZURUM TECHNICAL UNIVERSITY
2. ATATÜRK ÜNİVERSİTESİ, TIP FAKÜLTESİ
3. Mudanya University
Abstract
This case report details the unfortunate journey of a 59-year-old breast cancer survivor who developed secondary Retroperitoneal Fibrosis (RPF) in 2022. Despite diligent treatment efforts, her condition took a devastating turn when, in June 2023, she was diagnosed not only with persistent RPF but also with advanced liver, omental, and duodenal cancer. Tragically, her condition deteriorated rapidly, leading to her passing on day 41 following her presentation. This case underscores the challenges of diagnosing and treating RPF. It highlights the importance of considering cancer development in advanced RPF cases that do not respond to treatment, often leaving limited options for effective intervention.
Publisher
Acil Tip Uzmanlari Dernegi
Reference10 articles.
1. 1. ŞEKERCİ ÇA. Experience with treatment of retroperitoneal fibrosis: Collaboration of urology and nephrology departments for 26 years in Marmara University. 2017.
2. 2. Lee SJ, Eun JS, Kim MJ, Song YW, Kang YM. Association of retroperitoneal fibrosis with malignancy and its outcomes. Arthritis Research & Therapy. 2021;23:1-9.
3. 3. Runowska M, Majewski D, Puszczewicz M. Retroperitoneal fibrosis–the state-of-the-art. Reumatologia/Rheumatology. 2016;54(5):256-63.
4. 4. Chen T, Tian L, Fan D, Wu F, Lu J, Ding S. Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases. Clinical and Translational Oncology. 2019;21:373-9.
5. 5. Cansu DÜ. Retroperitoneal fibrozis: Ayırıcı tanı ve tedavi. Journal of Turkish Society for Rheumatology. 2022;14.